TherapeuticsMD (TXMD)
(Delayed Data from NSDQ)
$1.79 USD
-0.01 (-0.56%)
Updated Jul 25, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TXMD 1.79 -0.01(-0.56%)
Will TXMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TXMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TXMD
All You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to Buy
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
TXMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Organogenesis (ORGO) Lags Q3 Earnings and Revenue Estimates
TherapeuticsMD (TXMD) Reports Q2 Loss, Tops Revenue Estimates
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates
Other News for TXMD
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q4 2023
Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed
TherapeuticsMD: Q1 Earnings Snapshot
TherapeuticsMD Announces First Quarter 2024 Financial Results
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024